Lilly takes aim at Novo

Eli Lilly has taken Novo Nordisk to Medicines Australia over an alleged breach of the Code of Conduct for failing to "act promptly" to correct news articles that promoted the off-label use of Ozempic for weight loss/weight management in the mainstream media.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here